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Abstract
Background: The formation of new infectious human immunodeficiency type 1 virus (HIV-1)
mainly relies on the homo-multimerization of the viral structural polyprotein Pr55Gag and on the
recruitment of host factors. We have previously shown that the double-stranded RNA-binding
protein Staufen 1 (Stau1), likely through an interaction between its third double-stranded RNA-
binding domain (dsRBD3) and the nucleocapsid (NC) domain of Pr55Gag, participates in HIV-1
assembly by influencing Pr55Gag multimerization.
Results:  We now report the fine mapping of Stau1/Pr55Gag  association using co-
immunoprecipitation and live cell bioluminescence resonance energy transfer (BRET) assays. On
the one hand, our results show that the Stau1-Pr55Gag interaction requires the integrity of at least
one of the two zinc fingers in the NC domain of Pr55Gag but not that of the NC N-terminal basic
region. Disruption of both zinc fingers dramatically impeded Pr55Gag multimerization and virus
particle release. In parallel, we tested several Stau1 deletion mutants for their capacity to influence
Pr55Gag multimerization using the Pr55Gag/Pr55Gag BRET assay in live cells. Our results revealed that
a molecular determinant of 12 amino acids at the N-terminal end of Stau1 is necessary to increase
Pr55Gag multimerization and particle release. However, this region is not required for Stau1
interaction with the viral polyprotein Pr55Gag.
Conclusion: These data highlight that Stau1 is a modular protein and that Stau1 influences Pr55Gag
multimerization via 1) an interaction between its dsRBD3 and Pr55Gag zinc fingers and 2) a
regulatory domain within the N-terminus that could recruit host machineries that are critical for
the completion of new HIV-1 capsids.
Background
Human immunodeficiency type 1 (HIV-1) assembly con-
sists in the formation of new viral particles which is the
result of the radial multimerization of approximately
1,400 to 5,000 copies of the viral polyprotein Pr55Gag
(also named Gag) according to their quantification in
mature or immature particles, respectively [1-3]. Pr55Gag is
thought to contain most of the determinants required for
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viral assembly since the expression of Pr55Gag alone leads
to the formation and release of virus-like particles (VLPs),
structurally not really distinguishable from immature
HIV-1 [4-6]. Pr55Gag is a modular protein that contains 6
domains: matrix (MA), capsid (CA), nucleocapsid (NC),
p6 and two spacer peptides, p2 and p1. Each of these
domains plays specific roles during HIV-1 life cycle. Dur-
ing assembly, the MA domain, through its myristylated
moiety and its highly basic domain, anchors assembly
complexes to membranes [4-6]. Whether assembly takes
place at the inner leaflet of the plasma membrane or at the
multivesicular bodies (or both) is still under debate [7-
17].
Pr55Gag multimerization is likely initiated by NC/NC con-
tacts [18,19] probably when Pr55Gag is still in a cytosolic
compartment [20-23]. The basic amino acid stretch
present in NC is thought to non-specifically recruit RNA
that serves as a scaffold for multimerizing Pr55Gag [24-26].
Indeed, mutations abrogating the global positive charge
of this sub-domain compromise viral assembly [24,25].
NC also possesses two zinc fingers that are important for
the specific packaging of HIV-1 genomic RNA [27-29].
Recently, Grigorov et al. demonstrated the involvement of
both NC zinc fingers in Pr55Gag cellular localization and
HIV-1 assembly [30]. Similarly, the first NC zinc finger
was shown to be part of the minimal Pr55Gag sequence
required for multimerization (called the I domain) [5,6].
Since NC function during assembly can be mimicked by
its substitution with a heterologous oligomerization
domain [31,32], NC/NC contacts probably serve as a sig-
nal for the higher order multimerization of Pr55Gag under
the control of other domains. Indeed, the C-terminal third
of the CA domain and the spacer peptide p2 are part of the
I domain and have been shown by mutagenesis and struc-
tural analyses to be also very important players during
HIV-1 assembly [26,33-42].
The HIV-1 assembly process within the cell appears to be
tightly regulated in time and space and relies on the
sequential acquisition and release of host proteins that are
required for the cellular localization, multimerization and
budding of new capsids [4,43]. For instance, the ATP-
binding protein ABCE1/HP68 is important for the com-
pletion of Pr55Gag multimerization via a transient interac-
tion with the NC domain of Pr55Gag [44-47]. Adaptor
proteins 1, 2, 3 (AP-1; AP-2; AP-3) are involved in Pr55Gag
intracellular trafficking through their association with the
MA domain of Pr55Gag [12,48,49]. Finally, endosomal
sorting complex required for transport (ESCRT)-I and -III
machineries are recruited by the p6 domain of Pr55Gag
and are crucial for the budding and release of the neosyn-
thesized viral particles [50].
Staufen1 (Stau1) is also a Pr55Gag-binding protein that
influences HIV-1 assembly [51-53]. Stau1 belongs to the
double-stranded RNA-binding protein family [54,55] and
is involved in various cellular processes related to RNA.
Stau1 was first studied for its role in the transport and
localization of mRNAs in dendrites of neurons [56]. More
recently, Stau1 was identified as a central component of a
new mRNA decay mechanism termed Staufen-mediated
decay [57]. In addition to its functions in RNA localiza-
tion and decay, Stau1 can also stimulate translation of
repressed messengers containing structured RNA elements
in their 5'UTR [58].
Stau1 is a host factor that is selectively encapsidated into
HIV-1 [53]. Stau1 co-purifies with HIV-1 genomic RNA
and interacts with the NC domain of Pr55Gag [52,53] sug-
gesting that Stau1 assists NC's functions during the HIV-1
replication cycle. Stau1 levels in the producer cells are
important for HIV-1 since both Stau1 overexpression and
depletion using RNA interference affect HIV-1 infectivity
[52,53]. In addition to a putative role in HIV-1 genomic
RNA packaging [53], we recently showed that Stau1 mod-
ulates HIV-1 assembly by influencing Pr55Gag multimeri-
zation [51]. Indeed, using a new Pr55Gag multimerization
assay relying on bioluminescence resonance energy trans-
fer (BRET), we demonstrated that both Stau1 overexpres-
sion and depletion enhanced multimerization and
consequently increased VLP production. Although Stau1
and Pr55Gag interact in both cytosolic and membrane
compartments, this effect of Stau1 on Pr55Gag oligomeri-
zation was only observed in membranes, a cellular com-
partment in which Pr55Gag assembly primarily occurs.
However, the mechanism by which Stau1 influences HIV-
1 assembly at the molecular level remains unknown
although it is likely that it relies on the Stau1 interaction
with HIV-1 Pr55Gag.
Using co-immunoprecipitation and BRET assays, we
showed that both Pr55Gag NC zinc fingers are involved in
Stau1/Pr55Gag interaction as does the Stau1 dsRBD3 [52].
Unexpectedly, we found that the binding of Stau1 to NC
is not sufficient per se to fully enhance Pr55Gag multimer-
ization. To determine which domain of Stau1 modulates
the HIV-1 Pr55Gag multimerization process, we analyzed
several Stau1 deletion mutants for their capacity to
enhance Pr55Gag  multimerization. Using the Pr55Gag/
Pr55Gag BRET assay either in live cells or after cell fraction-
ation, we showed that the first 88 amino acids at the N-
terminal of Stau1 confer the capacity to enhance both
Pr55Gag multimerization and VLP production. Although
unable to enhance multimerization, this mutant was still
able to interact with Pr55Gag. This study provides impor-
tant new information about the molecular determinants
required for Stau1 function in HIV-1 assembly.Retrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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Methods
Cell culture and reagents
Human embryonic kidney fibroblasts (HEK 293T) were
cultured in Dulbecco's Modified Eagle Medium (Invitro-
gen) supplemented with 10% cosmic calf serum
(HyClone) and 1% penicillin/streptomycin antibiotics
(Multicell). Transfections were carried out using either the
calcium phosphate precipitation method or the Lipo-
fectamine 2000 reagent (Invitrogen). For Western blots,
mouse and rabbit HRP-coupled secondary antibodies
were purchased from Dako Cytomation and signals were
detected using the Western Lightning Chemiluminescence
Reagent Plus (PerkinElmer Life Sciences). Signals were
detected with a Fluor-S MultiImager apparatus (Bio-Rad).
Anti-Na-K ATPase antibodies were kindly provided by Dr.
Michel Bouvier.
Plasmid construction
The construction of pcDNA3-RSV-Stau155-HA3, pcDNA3-
RSV-Stau1F135A-HA3, pcDNA-RSV-Stau1ΔNt88-HA3, pCMV-
Stau155-YFP, pCMV-Stau1F135A-YFP, pCMV-Stau1ΔNt88-
YFP, pCMV-Stau1ΔdsRBD3-YFP, pCMV-Pr55Gag-Rluc,
pCMV-Pr55Gag-YFP, pCMV-NC-p1-YFP and pCMV-CA-
p2-NC-p1-Rluc was reported before [51-54,59]. The
HxBRU PR-provirus and the Rev-independent Pr55Gag
expressor were described before [51,53,60].
To construct pcDNA-RSV-Stau1ΔNt37-HA3, a polymerase
chain reaction (PCR) was performed using pcDNA3-RSV-
Stau155-HA3  as template, sense (5'-ATCAGGTACCAT-
GGGTCCATTTCCAGTTCCACCTTT-3') and anti-sense (5'-
CACATCTAGATCATTTATTCAGCGGCCGCACTGAG-
CAGCGT-3') oligonucleotide primers and the Phusion
DNA polymerase (New England Biolabs). The PCR prod-
uct was purified and digested with KpnI and XbaI restric-
tion enzymes (Fermentas) and then cloned into the KpnI/
XbaI cassette of pCDNA3-RSV.
To generate pcDNA-RSV-Stau155-Flag plasmid, oligonu-
cleotides (5'-GGCCTTGATTACAAGGATGACGAT-
GACAAG-3' and 5'-
GGCCCTTGTCATCGTCATCCTTGTAATCAA-3') were
hybridized and then inserted into the NotI sites of pcDNA-
RSV-Stau155-HA3 in replacement of the HA-tag. For the
construction of pcDNA-RSV-Stau1ΔNt88-Flag, the EcoRI
fragment of pcDNA-RSV-Stau1ΔNt88-HA3 that contained
the mutated Stau1 sequence, was cloned into EcoRI-
digested pcDNA-RSV-Stau155-Flag plasmid.
The expressors of NC-p1-YFP and Pr55Gag-YFP mutants
were PCR amplified using the PCR all-around technique
[59] to generate the following mutations: the C15S muta-
tion was introduced with the primer pair 5'-AAGAGTT-
TCAATTGTGGCAAA-3' and 5'-
GAAACTCTTAACAATCTTTCT-3'; the C49S mutation was
generated with the primer pair 5'-GATAGTACTGAGA-
GACAGGCT-3' and 5'-AGTACTATCTTTCATTTGGTG-3';
R7S, R10S and K11S mutations (R7 mutant) were intro-
duced with the primer pair 5'-TTTAGCAACCAAAGCTC-
GATTGTTAAGTGTTTC-3' and 5'-
AATCGAGCTTTGGTTGCTAAAATTGCCTCTCTG-3'. PCR
reactions were carried out with the Phusion enzyme (New
England Biolabs) at 95°C for 50 s, 55°C for 60 s and
72°C for 90 s, for 18 cycles. Resulting products were incu-
bated with 10 units of DpnI enzyme (Fermentas) and then
transformed into competent bacteria. Positive clones con-
taining the mutation(s) were screened by restriction and
sequencing analyses. The double zinc fingers mutant
expressors (pCMV-Pr55Gag C15–49S-YFP and pCMV-NC-
p1C15–49S-YFP) were generated by PCR with the oligonu-
cleotide primer pair for the C49S mutation using the cor-
responding plasmids that contain the C15S mutation.
Membrane flotation assays and S100-P100 fractionation
Forty hours post-transfection, cell extracts were prepared
by passing the cells 20 times through a 23G1 syringe in TE
(10 mM Tris pH7.4, 1 mM EDTA pH 8) containing 10%
sucrose and proteases inhibitors (Roche). Nuclei were
removed by centrifugation at 1,000 × g. Resulting cyto-
plasmic extracts were separated using the membrane flo-
tation assay as previously described [51]. Membrane-
associated complexes were collected (fractions 2 and 3).
Membranes were solubilized by treating these complexes
with 0.5% Triton X-100 at room temperature for 5 min-
utes and samples were subjected to S100/P100 fractiona-
tion as previously described [51] by ultracentrifugation at
100,000 × g for 1 h at 4°C. Supernatants (S100 fractions)
and pellets (P100 fractions) were collected and analyzed
by Western blotting using anti-CA, anti-HA and anti-Na-K
ATPase mouse antibodies.
BRET assays
293T cells were transfected in 6-well plates with constant
amounts of the Rluc-fused energy donor expressor (25–75
ng), increasing amounts of YFP-fused acceptor expressor
(0.25–2  μg) and Stau1-HA3-expressing plasmid (1–1.5
μg) when indicated. 48 hours post-transfection, cells were
collected in PBS-EDTA 5 mM and diluted to approxi-
mately 2 × 106 cells/mL. BRET assays were performed as
described before [51,52] using a Fusion α-FP apparatus
(Perkin-Elmer). In this interaction assay, an X-Rluc fusion
protein is used as an energy donour whereas a Y-YFP
fusion protein is an energy acceptor. When the two fusion
proteins are in close proximity (< 100Å), non-radiative
resonance energy is transferred from X-Rluc to Y-YFP
which in turn emits measurable fluorescence. This can be
quantified by the calculation of the BRET ratio which
allows detection of protein-protein interactions. The BRET
ratio was defined as [(emission at 510 to 590 nm)-(emis-
sion at 440 to 500 nm) × Cf]/(emission at 440 to 500Retrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
Page 4 of 19
(page number not for citation purposes)
nm), where Cf corresponds to (emission at 510 to 590
nm)/(emission at 440 to 500 nm) when Rluc fused pro-
tein is expressed alone. The total YFP activity/Rluc activity
ratio reflects the relative levels of the two fusion proteins
in the cells. The BRET ratio increases with the total YFP
activity/Rluc activity ratio since more YFP-fused molecules
bind to Rluc-fused proteins. For Pr55Gag multimerization
assays, in order to avoid misinterpretation due to varia-
tions in relative levels of the Pr55Gag fusion proteins,
changes in the Pr55Gag/Pr55Gag  BRET ratios following
Stau1 overexpression were always analyzed at similar total
YFP activity/Rluc activity ratio.
When Pr55Gag/Pr55Gag BRET assays were performed fol-
lowing membrane flotation assays, the Rluc substrate coe-
lenterazine H (NanoLight Technology) was added to 90
μL of each fraction and BRET ratio was determined as in
live cells. BRET ratios in fractions 1, 3, 4, 5 and 6 were not
considered because luciferase activity was too low in these
fractions and hence, did not lead to the determination of
a reliable BRET ratio.
For CA-p2-NC-p1-Rluc/Stau1-YFP and Stau155-Rluc/NC-
p1-YFP interaction assays, BRET ratios were always com-
pared at similar total YFP activity/Rluc activity ratio. The
BRET ratio determined in the context of the expression of
the unfused YFP protein (YFP) corresponds to non spe-
cific interactions between the energy donor and the YFP.
Hence, this background BRET ratio was always subtracted
from all BRET ratios and was set to 0%. The BRET ratio
determined following co-expression of the energy donor
and the wild type energy acceptor was set to 100%.
For dose-response Pr55Gag/Pr55Gag BRET assays, 293T cells
were transfected with fixed amounts of pCMV-Pr55Gag-
Rluc and pCMV-Pr55Gag-YFP and increasing amounts
(0.25–2  μg) of different Stau1-HA3  expressors. BRET
assays were performed 48 hours post-transfection as
described above.
Co-immunoprecipitation assays
293T cells were transfected with Stau155-flag and Gag
expressors using Lipofectamine 2000 (Invitrogen).
Twenty hours post-transfection, cells were collected in
lysis buffer (150 mM NaCl, 50 mM Tris pH 7.4, 1 mM
EDTA, 1% Triton X-100) containing proteases inhibitors
(Roche). Each cell lysate (1.5 mg of proteins) was pre-
cleared with IgG-agarose (Sigma-Aldrich) for 1 h at 4°C
and then subjected to immunoprecipitation using 15 μL
of anti-Flag M2 affinity gel (Sigma-Aldrich) for 2 h at 4°C.
Immune complexes were washed 3 times during 5 min-
utes with cold lysis buffer, eluted with the Flag peptide
(Sigma-Aldrich), resolved in SDS-containing acrylamide
gels and analyzed for their content in Stau1 and Gag pro-
teins by Western blotting using mouse monoclonal anti-
Flag (Sigma-Aldrich), anti-GFP (Roche) and anti-CA anti-
bodies.
Virus-like particle purification
293T cells were transfected with Stau155-HA3 and Gag
expressors using Lipofectamine 2000 (Invitrogen).
Twenty hours post-transfection, supernatants were col-
lected and cleared through a 0.45 μm filter. VLPs were pel-
leted through a sucrose cushion (20% in Tris-NaCl buffer)
by ultracentrifugation during 1 hour at 220,000 × g. VLPs
were resuspended in Tris-NaCl buffer and analyzed by
Western blotting using anti-CA antibodies. Pr55Gag signals
in the VLPs and the cell extracts were quantitated using the
Quantity One (version 4.5) software (Bio-Rad).
Results
Both NC zinc fingers mediate Stau1/Pr55Gag interaction
The interaction between Stau1 and Pr55Gag is likely a crit-
ical determinant for Stau1 function in HIV-1 assembly.
Indeed we previously showed that a single point mutation
in the third double-stranded RNA-binding domain of
Stau1 (Stau1F135A) prevented both the association of the
mutant to Pr55Gag and the Stau1-mediated increase of
HIV-1 assembly [51-53]. Moreover, we showed that
Stau1/Pr55Gag interaction required the NC domain [52]
that contains motifs involved in several steps during HIV-
1 assembly. As a first step, to understand the molecular
mechanisms underlying Stau1 influence on HIV-1 assem-
bly, we identified which NC sub-domain is required for
Pr55Gag/Stau1 association using the BRET assay with
Stau155-Rluc and wild type or mutant NC-p1-YFP fusion
proteins. Four NC mutants were constructed. Point muta-
tions were introduced in the NC-p1-YFP fusion protein to
disrupt the first zinc finger (NC-p1C15S-YFP), the second
(NC-p1C49S-YFP), both zinc fingers (NCp1-YFPC15–49S) or
the N-terminal basic residues (NCp1-YFPR7)(Figure 1A).
For this mutant, Arg7, Arg10 and Lys11 were substituted for
serines (Figure 1A). Mutations in this basic region were
previously reported to severely affect HIV-1 assembly [24].
Constructs encoding the wild type and mutants NC fusion
proteins were transfected in 293T cells and their expres-
sion patterns were analyzed by Western blotting using an
anti-GFP antibody. Figure 1B shows that wild type and
mutant NC-p1-YFP proteins were well expressed and have
the expected molecular weight. However, for unknown
reasons, NC-p1C15–49S-YFP was always slightly less
expressed than the other NC-p1-YFP proteins.
These proteins were then tested for their capacity to inter-
act with Stau155 using the BRET assay in live 293T cells
(Figure 2A). This technique allows us to detect protein-
protein interaction in live cells between Rluc-fused Stau1
and NC-p1-YFP molecules (Figure 2A). Indeed, when the
two fusion proteins are in close proximity (≤ 100Å) as a
consequence of Stau1-NC interaction, non-radiative reso-Retrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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Design and expression of NC mutants used for the fine mapping of Stau1/NC interaction Figure 1
Design and expression of NC mutants used for the fine mapping of Stau1/NC interaction. (A) Schematic repre-
sentation of Pr55Gag with emphasis on the sequence of NC and its two zinc fingers. Several point mutations were introduced in 
the basic region or in the zinc fingers of NC-p1-YFP fusion protein to generate four mutants. (B) 293T cells were transfected 
with YFP, NC-p1-YFP and mutated NC-p1-YFP expressors. 48 hours post-transfection, cell lysates were prepared and ana-
lyzed by Western blotting using anti (α)-GFP antibodies.
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The NC zinc fingers mediate Stau1/Pr55Gag interaction Figure 2
The NC zinc fingers mediate Stau1/Pr55Gag interaction. (A) Top: schematic representation of the Stau1/NC-p1 BRET 
assay. Bottom: 293T cells were transfected with constant amounts of pCMV-Stau155-Rluc and increasing amounts of wild type 
or mutated NC-p1-YFP expressors. 48 hours post-transfection, BRET ratios were determined and plotted in function of their 
corresponding total YFP/Rluc ratio which allows us to compare BRET ratios at the same relative expression levels of fusion 
proteins. This figure is representative of four independent experiments. (B) BRET ratios were compared at identical total YFP/
Rluc ratio and corrected by subtracting the background BRET ratio calculated for unfused YFP and Stau155-Rluc co-expression 
(see Methods). The corrected BRET ratio for Stau155-Rluc and wild type NC-p1-YFP coexpression was arbitrarily set to 100%. 
These results are representative of four independent experiments. (C) 293T cells were transfected with Pr55Gag-YFP or 
Pr55Gag C15-49S-YFP expressors. Twenty hours post-transfection, lysates were analyzed by Western blotting using anti-GFP anti-
bodies. (D) Following Stau155-Flag and wild-type or mutated Pr55Gag-YFP co-expression, 293T cell lysates were submitted to 
immunoprecipitation using anti-Flag antibodies. Immune complexes were analyzed for their content of YFP-fused proteins and 
Stau1-Flag using anti (α)-GFP and anti (α)-Flag antibodies, respectively. Anti (α)-GAPDH antibodies were used as loading con-
trols. This figure is representative of four independent experiments.
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nance energy is transferred from the emitting Rluc to YFP
which becomes excited and in turn emits fluorescence. A
BRET ratio is calculated for each condition (see Methods).
To perform BRET saturation experiments, we transfected
293T cells with constant amounts of pCMV-Stau155-Rluc
plasmid and increasing amount of different NC-p1-YFP
expressors. BRET assays were performed 48 hours post-
transfection (Figures 2A, B). BRET saturation experiments
allowed us to compare BRET ratios at the same relative
ratio between fusion proteins (comparable total YFP/Rluc
ratio) (Figure 2B). As expected, we readily detected a spe-
cific BRET between wild type NC-p1-YFP and Stau155-Rluc
(arbitrarily set to 100% in Figure 2B) as compared to co-
expression of Stau155-Rluc and YFP alone (Figures 2A, B).
Mutations that modify the NC N-terminal basic region
did not affect the binding of NC to Stau1 since the satura-
tion profile for Stau1/NC-p1R7-YFP BRET was almost
identical to the one obtained with Stau1/NC-p1-YFP (Fig-
ures 2A, B). In contrast, when the two zinc fingers were
mutated (NC-p1C15–49S-YFP), the BRET saturation profile
was comparable to that obtained with YFP alone and
hence, mostly attributable to background (Figure 2A).
When compared to NC-p1-YFP at the same total YFP/Rluc
ratio, the corrected BRET ratio was decreased by 80% (Fig-
ure 2B). This suggests that NC-p1C15–49S-YFP lost almost
completely its ability to interact with Stau1. Mutations in
individual zinc finger (NC-p1C15S-YFP and NC-p1C49S-
YFP) only affected the BRET ratio by 30–40% and these
two mutants showed an intermediate profile (Figures 2A,
B).
This suggests that the integrity of at least one NC zinc fin-
gers is required for Stau1/NC interaction.
We used a second technique to confirm the involvement
of both zinc fingers in Stau1-NC interaction in the context
of full-length Pr55Gag. We generated a Pr55Gag-YFP-
expressing plasmid in which both zinc fingers were
mutated (Pr55Gag C15–49S-YFP)(see below). As shown in
Figure 2C, this mutant was expressed to the same level as
the wild-type Pr55Gag-YFP and migrated in SDS-contain-
ing acrylamide gels at the expected molecular weight (80
kDa). Following co-expression of Flag-tagged Stau155 with
wild type or mutated Pr55Gag-YFP in 293T cells (Figure
2D, upper panel), Stau155-Flag-containing complexes
were immunoprecipitated using anti-Flag antibodies.
Immunopurified material was analyzed by Western blot
using monoclonal anti-GFP and anti-Flag antibodies (Fig-
ure 2D, lower panel). As expected, Pr55Gag-YFP success-
fully co-precipitated with Stau155-Flag. In contrast,
despite similar levels of expression in the cell (Figure 2D,
upper panel), the Pr55Gag C15–49S-YFP mutant was not effi-
ciently co-immunoprecipitated with Stau155-Flag as com-
pared to wild type (Figure 2D, lower panel) suggesting
that the association between this mutant and Stau155 is
impaired. Pr55Gag C15S-YFP and Pr55Gag C49S-YFP mutants
retained some association with Stau155-Flag although
they displayed lower binding capability than the wild type
Pr55Gag (not shown), consistent with the BRET assay. Alto-
gether, these results show that the two zinc fingers within
the NC domain of Pr55Gag mediate its association with
Stau1. Moreover, this suggests that Stau1 influences those
assembly processes that depend on NC zinc fingers.
Mutations in the NC zinc fingers severely compromises 
Pr55Gag multimerization and release
The fact that Stau1 influences HIV-1 Pr55Gag multimeriza-
tion and associates with NC zinc fingers is consistent with
previous reports showing that these structural motifs are
important in HIV-1 assembly [29,30,46]. To confirm this
hypothesis in a system that tests direct interaction, we
evaluated the consequence of mutations in the Pr55Gag
zinc fingers on VLP release and on Pr55Gag dimerization
using the BRET assay. 293T cells were transfected with
Pr55Gag-YFP and Pr55Gag C15–49S-YFP expressors (Figure
3A). Twenty-four hours post-transfection, VLPs were col-
lected from the supernatant and cells were collected. In
the cell extracts, Pr55Gag-YFP and Pr55Gag C15–49S-YFP were
present at similar levels (Figure 3B, left panel). In contrast,
the release of Pr55Gag C15–49S-YFP in the cell supernatant
was reduced by 95.1% (+/- 3.4 S.D.; n = 3) as compared to
that of Pr55Gag-YFP (Figure 3B, right panel) suggesting
that this mutant failed to efficiently assemble. Used as a
negative control, MA-CAWM184–185AA-YFP (Figure 3A), a
Pr55Gag mutant that was shown to be almost completely
monomeric in the cell and unable to generate VLPs
[26,51], was not detected in the cell supernatant although
it was expressed at higher levels than Pr55Gag-YFP and
Pr55Gag C15–49S-YFP in the cell (Figure 3B).
Then, we determined whether mutations in the zinc fin-
gers affect Pr55Gagmultimerization. Using the BRET assay
in live cells, we tested the capacity of Pr55Gag C15–49S-YFP
to dimerize with Pr55Gag-Rluc, the wild-type Pr55Gag-YFP
being used as control (Figure 3A). As shown in Figure 3C,
Pr55Gag homo-dimerization was readily detectable with a
BRET ratio of 0.09 at saturation. In contrast, Pr55Gag C15–
49S-YFP failed to interact with Pr55Gag-Rluc in the BRET
assay since its saturation curve was similar to the one
obtained with the monomeric Gag mutant MA-CAWM184–
185AA-YFP. Altogether, these results clearly show that, in
the context of VLP assembly, Pr55Gag zinc fingers are
important for multimerization and release. This suggests
that Stau1, through its binding to the NC zinc fingers
could influence crucial processes that are controlled by
these motifs during HIV-1 assembly.Retrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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Disruption of both Pr55Gag zinc fingers affects VLP production Figure 3
Disruption of both Pr55Gag zinc fingers affects VLP production. (A) Schematic representation of the Gag fusion pro-
teins used in the BRET and release assays. (B) Wild-type or mutated YFP-fused Gag proteins were expressed in 293T cells for 
twenty-four hours. VLPs in the cell supernatant were purified. Cell lysates and VLPs were analyzed by Western blotting using 
anti (α)-GFP antibodies. Anti (α)-GAPDH antibodies were used as loading controls. This figure is representative of three inde-
pendent experiments. (C) 293T cells were transfected with constant amounts of pCMV-Pr55Gag-Rluc and increasing amounts 
of wild type or mutated YFP-fused Gag expressors. Twenty-four hours post-transfection, cells were collected and BRET ratios 
determined. BRET ratios are plotted in function of their corresponding total YFP/Rluc ratio. This figure is representative of 
three independent experiments.
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The N-terminal domain of Stau1 is required for the Stau1-
mediated enhancement of Pr55Gag multimerization
We previously showed that Stau1 over-expression or
depletion from cells enhanced Pr55Gag multimerization.
To determine if the binding of Stau1 to NC is sufficient for
Pr55Gag multimerization or whether other determinants
within Stau1 are required for this process, we tested sev-
eral Stau1 deletion mutants for their capacity to enhance
assembly (Figure 4A). To this end, we used the previously
described Pr55Gag/Pr55Gag BRET assay in live 293T cells as
a sensor for changes in Pr55Gag multimerization (Figure
4B)[51]. Indeed, Rluc- and YFP-fused Pr55Gag co-expres-
sion generates a positive BRET ratio in live cells as a con-
sequence of Pr55Gag multimerization. In order to compare
BRET ratio changes at the same relative levels of Pr55Gag
fusion proteins, we performed BRET saturation experi-
ments. As previously reported, when Stau155-HA3 was co-
expressed with Pr55Gag-Rluc and Pr55Gag-YFP in 293T
cells, the Pr55Gag/Pr55Gag BRET ratio increased as a conse-
quence of enhanced Pr55Gag  multimerization (Figures
4B)[51]. Several HA-tagged Stau1 deletion mutants were
then tested for their capacity to enhance Pr55Gag/Pr55Gag
BRET ratio and hence, Pr55Gag multimerization. Interest-
ingly, Stau1ΔNt88-HA3, a mutant that lacks the dsRBD2 as
a consequence of the deletion of the first N-terminal 88
amino acids (Figure 4A) was unable to significantly
increase the Pr55Gag/Pr55Gag BRET ratio in live cells [1.29
(+/-0.13 S.D. n = 4)-fold induction] as compared to
Stau155-HA3 [2.04 (+/-0.09 S.D. n = 4)-fold induction]
(Figures 4B, D). Western blot analyses showed that
Stau1ΔNt88 was expressed at levels comparable to that of
wild type Stau1-HA3 (Figure 4C). Nevertheless, a moder-
ate increase in Pr55Gag multimerization was seen when
Stau1ΔNt88 was highly over-expressed although its effect on
Pr55Gag  multimerization was always weaker than that
obtained with Stau155-HA3  (see below). In contrast,
mutants with deletion in dsRBD4, dsRBD5 or tubulin-
binding domain (TBD) all enhanced the Pr55Gag/Pr55Gag
BRET ratio at levels comparable to that obtained with
Stau155-HA3 (data not shown). As control, Stau1F135A-
HA3, a Stau1 mutant that does not bind Pr55Gag, failed to
stimulate Pr55Gag multimerization (data not shown)[51].
Therefore, the Stau1-mediated enhancement of Pr55Gag
multimerization requires two determinants: dsRBD3 for
the association with NC and the N-terminus.
Stau1ΔNt88 still interacts with HIV-1 Gag
To test the ability of Stau1ΔNt88 to interact with Pr55Gag, we
performed BRET assays between Stau1ΔNt88-YFP and a
truncated Pr55Gag (CA-p2-NC-p1-Rluc) that was previ-
ously shown by the co-immunoprecipitaton assay to
interact as efficiently with Stau1 as full-length Pr55Gag [52]
and (Figure 5A). To verify efficiency between these mole-
cules, Stau1ΔNt88-YFP and Stau155-YFP were expressed
(Figure 5B) and the BRET saturation profiles determined
(Figure 5C). Curves obtained with Stau155-YFP and with
Stau1ΔNt88-YFP were almost similar suggesting that
Stau1ΔNt88mutant retains its capacity to bind to Pr55Gag.
The BRET ratios were specific since the Gag-binding defi-
cient mutant Stau1ΔdsRBD3-YFP showed reduced BRET
ratios. In independent saturation experiments (Figure
5D), the specific BRET ratio following co-expression of
Stau1ΔNt88-YFP and CA-p2-NC-p1-Rluc was comparable
[105.7 (+/- 18.1 S.D.)% of CA-p2-NC-p1/Stau155 cor-
rected BRET ratio] to that obtained with wild type Stau155-
YFP at similar total YFP/Rluc ratio. We could not detect a
specific BRET signal when Stau1F135A-YFP [52] was used
[1.3 (+/- 22.1 S.D.)% of CA-p2-NC-p1/Stau155 corrected
BRET ratio].
The ability of Stau1ΔNt88 to associate with Pr55Gag was con-
firmed in co-immunoprecipitation assays (Figure 5E).
Pr55Gag  and flag-tagged Stau1 or Stau1ΔNt88  were co-
expressed in 293T cells (Figure 5E, left panel) and proteins
in the cell extracts were immunoprecipitated using anti-
flag antibody. Western blot analyses of the immune com-
plexes showed that Pr55Gag successfully co-precipitated in
a specific manner with both Stau155-flag and Stau1ΔNt88-
FLAG (Figure 5E, right panel). These results show that,
although Stau1ΔNt88 is unable to stimulate Pr55Gag mul-
timerization, its interaction with Pr55Gag was maintained.
This result suggests that Stau1 association to Pr55Gag is not
sufficient to influence HIV-1 assembly and that Stau1 N-
terminus contains a regulatory element that is important
for its function during this process.
Stau1ΔNt88-HA3 does not enhance the assembly of 
membrane-associated Pr55Gag complexes
We previously showed that the Stau1-mediated enhance-
ment of Pr55Gag multimerization occurs in membrane
compartments [51]. Therefore, to test whether Stau1ΔNt88-
HA3 reaches the membranes and whether the whole cell
analysis described above masked an effect of Stau1ΔNt88-
HA3 on assembly, membrane-associated virus assembly
was analyzed in the context of Stau1ΔNt88-HA3 or Stau155-
HA3  over-expression. Cytoplasmic extracts from trans-
fected 293T cells were analyzed by the membrane flota-
tion assay (Figure 6A)[51]. This assay allows the
separation of membrane-associated complexes (fraction
2; M) from the cytosolic ones (fractions 7, 8 and 9; Cy).
First, Western blot analysis indicated that Stau1ΔNt88-HA3
was both over-expressed and present in membranes at the
same levels as Stau155-HA3 (data not shown). As previ-
ously described [51], Pr55Gag/Pr55Gag BRET was readily
detected in the membrane fraction (BRET ratio of 0.33)
but not in the cytosolic fractions consistent with the fact
that HIV-1 assembly occurs on cellular membranes (Fig-
ure 6B)[10,61,62]. Moreover, as reported before, Stau155-
HA3 over-expression led to an increase of 1.6-fold in the
Pr55Gag/Pr55Gag BRET ratio in the membrane fraction butRetrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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The N-terminus of Stau1 is required for the modulation of Pr55Gag multimerization in live cells Figure 4
The N-terminus of Stau1 is required for the modulation of Pr55Gag multimerization in live cells. (A) Schematic 
representation of HA-tagged Stau155 expressors. Stau1 double-stranded RNA-binding domains (dsRBD) and tubulin-binding 
domain (TBD) are represented as grey and black boxes, respectively. (B) Schematic representation of the Pr55Gag/Pr55Gag 
BRET assay. This assay is used as a sensor of Pr55Gag multimerization. 293T cells were transfected with constant amounts of 
pCMV-Pr55Gag-Rluc and increasing amounts of pCMV-Pr55Gag-YFP. A constant amount of a third plasmid expressing Stau155-
HA3 or Stau1ΔNt88-HA3 was included in the transfection procedure. Rluc activity as well as transmitted and total YFP activities 
was measured. BRET ratios were plotted in function of their corresponding total YFP/Rluc ratio which allows us to compare 
BRET ratios at the same relative expression levels of Pr55Gag fusion proteins. This figure is representative of four independent 
experiments. (C) Cells corresponding to the four last points of each curve from Figure 4B were lysed. Cell lysates were ana-
lyzed by Western blotting using anti (α)-HA antibodies for their content in over-expressed Stau1 proteins. *: Non-specific 
labelling typically obtained with the anti-HA antibody. (D) BRET ratios were compared at comparable total YFP/Rluc ratio. The 
BRET ratio corresponding to the pr55Gag fusions expressed alone was arbitrarily set to 1. The BRET induction levels were then 
determined and are shown in the graph. These results are representative of 4 experiments.
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Stau1ΔNt88 interacts with HIV-1 Gag in live cells Figure 5
Stau1ΔNt88 interacts with HIV-1 Gag in live cells. (A) Schematic representation of the Stau1/CA-p2-NC-p1 BRET assay. 
(B) 293T cells were cotransfected with CMV-CA-p2-NC-p1-Rluc and Stau1-YFP expressors. 48 hours post-transfection, 
Stau155-YFP and Stau1ΔNt88-YFP contents in the cells were analyzed by Western blotting using anti (α)-GFP antibodies. (C) 
293T cells were transfected with constant amounts of CA-p2-NC-p1-Rluc-expressing plasmid and increasing amounts of wild-
type or mutated YFP-fused Stau1 expressors. Twenty four hours post-transfection, live transfected cells were used for CA-p2-
NC-p1/Stau1 BRET assays. BRET ratios are plotted in function of their corresponding total YFP/Rluc ratio. n = 4. (D) BRET 
ratios were compared at identical total YFP/Rluc ratio and corrected by subtracting the background BRET ratio calculated for 
unfused YFP and CA-p2-NC-p1-Rluc co-expression. The corrected BRET ratio between CA-p2-NC-p1-Rluc and Stau155-YFP 
was arbitrarily set to 100%. n = 4. (E) 293T cells were co-transfected with Pr55Gag and wild-type or N-terminally truncated 
Stau1-Flag expressors. Twenty-four hours post-transfection, cell extracts were prepared and subjected to immunoprecipita-
tion using anti-Flag antibodies. Cell lysates and immune complexes were analyzed by Western blotting using anti (α)-Flag and 
anti (α)-CA antibodies. Anti (α)-GAPDH antibodies were used as a loading control. n = 2.
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Stau1ΔNt88-HA3 does not affect the multimerization of membrane-associated Pr55Gag Figure 6
Stau1ΔNt88-HA3 does not affect the multimerization of membrane-associated Pr55Gag. (A) Schematic representa-
tion of the experimental procedure. 293T cells were transfected with Pr55Gag-Rluc, Pr55Gag-YFP and Stau1-HA3 expressors. 48 
hours post-transfection, cytoplasmic extracts were prepared and subjected to the membrane flotation assay. (B) Pr55Gag/
Pr55Gag BRET ratio was determined in each collected fraction. BRET ratios in fractions 1, 3, 4, 5 and 6 were omitted because 
Rluc activity in these fractions was too low to provide a reliable BRET ratio. (C) Schematic representation of the experimental 
procedure. 293T cells were transfected with HxBRU PR-provirus and Stau1-HA3 expressors. 24 hours post-transfection, cyto-
plasmic extracts were prepared and subjected to the membrane flotation assay. Membrane fractions were collected and 
treated with 0.5% Triton X-100 during 5 minutes at room temperature in order to solubilize membranes. Resulting samples 
were subjected to ultracentrifugation at 100,000 × g during 1 hour. (D) Resulting supernatants (S100; S) and pellets (P100; P) 
were analyzed by Western blotting using anti (α)-CA, anti (α)-Na-K ATPase and anti (α)-HA antibodies. *: Non-specific label-
ling typically obtained with the anti-HA antibody.
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not in the cytosolic fraction [51]. In contrast, there was lit-
tle change in the ability of Pr55Gag to multimerize in the
membrane fraction when the mutant Stau1ΔNt88-HA3 was
over-expressed.
The inability of Stau1ΔNt88-HA3 to modulate Pr55Gag mul-
timerization was then tested in the context of provirus-
driven immature HIV-1 production. We had previously
shown that Stau1-mediated increase in Pr55Gag multimer-
ization correlated with a partial resistance to mild deter-
gent treatment of membrane-associated Pr55Gag
complexes [51]. Stau1 expressors and the protease-defec-
tive provirus HxBRU PR-were cotransfected in 293T cells.
Forty hours post-transfection, membrane flotation assays
on cytoplasmic extracts were performed and fractions con-
taining membrane-associated complexes were collected.
The resulting complexes were then subjected to ultracen-
trifugation at 100,000 × g for 1 hour (Figure 6C). In this
assay, insoluble or high-density complexes are found in
the pellet (P100) whereas proteins that are soluble or
components of small complexes are retained in the super-
natant (S100). Resulting P100 and S100 fractions were
analyzed by Western blot. As previously shown [51],
Pr55Gag as well as the membrane marker, sodium potas-
sium (Na-K) ATPase, were primarily found in the P100
fraction because Pr55Gag was membrane-associated (data
not shown). This was observed whether Stau1 proteins
were over-expressed or not (data not shown). To separate
Pr55Gag complexes from membranes, membranes were
solubilized with 0.5% Triton-X100. These experiments
were done at room temperature to also solubilize lipid
rafts and other membrane compartments that are deter-
gent-resistant at 4°C. As reported before, membrane solu-
bilization prior to S100/P100 fractionation resulted in a
complete shift of Pr55Gagcomplexes and Na-K ATPase into
the S100 fraction (Figure 6D)[51]. Stau155-HA3 overex-
pression led to a partial resistance of 33% of Pr55Gag com-
plexes to Triton-X100 treatment, likely as a consequence
of enhanced Pr55Gag multimerization (Figure 6D). In con-
trast, Stau1ΔNt88-HA3, as well as Stau1F135A-HA3 used as
control [51,52] failed to increase the density of Pr55Gag
complexes. Altogether, these results support the conclu-
sion that the N-terminus of Stau1 is required for Stau1-
mediated increase of Pr55Gag  assembly during HIV-1
assembly.
Amino acids 26 to 37 of Stau155 are important for its 
function in Pr55Gag multimerization
To more precisely map the functional determinant within
the N-terminal region that is involved in the regulation of
Pr55Gag  multimerization, we generated two additional
deletion mutants, Stau1ΔNt25-HA3 and Stau1ΔNt37-HA3 and
confirmed their expression (Figure 7A). Using the
Pr55Gag/Pr55Gag BRET assay in live 293T cells, Stau1ΔNt25-
HA3 enhanced the BRET ratio like wild type Stau155-HA3
suggesting that the first 25 amino acids are not required
for this function (Figure 7B). In contrast, Stau1ΔNt37-HA3
did not significantly enhance the BRET ratio and gener-
ated a BRET curve similar to that obtained with
Stau1ΔNt88-HA3. Expression of increasing amounts of
Stau155-HA3 or Stau1ΔNt25-HA3 (Figure 7C) led to a com-
parable increases of Pr55Gag/Pr55Gag BRET ratio up to
2.16–2.34-fold (Figure 7D). In contrast, expression of
Stau1ΔNt37-HA3  or Stau1ΔNt88-HA3  had no effect on
Pr55Gag/Pr55Gag BRET ratio when their expression is rela-
tively low. However, when highly expressed, they slightly
enhanced the BRET ratio by 1.34–1.47-fold. These results
suggest that the sequence located between amino acids 26
and 37 is important for Stau1-mediated enhancement of
Pr55Gag multimerization and show that Stau1 acts on
Pr55Gag multimerization in a dose-dependent manner.
Effect of Stau1 N-terminal mutants on VLP production
We already showed that Stau1 over-expression, likely as a
consequence of its role in multimerization, also increases
VLP release from the cell [51]. Therefore, considering the
inability of Stau1ΔNt88 to influence Pr55Gag multimeriza-
tion (Figure 4), we suspected that over-expression of
Stau1ΔNt88 would not stimulate VLP production. To test
this idea, Pr55Gag and either Stau155-HA3 or Stau1ΔNt88-
HA3 were co-expressed in 293T cells. Twenty-four hours
post-transfection, the levels of VLP release were analyzed
by Western blotting (Figure 8A). As expected, a 2-fold
increase in the expression of Stau155-HA3 as compared to
endogenous Stau1 resulted in a 2.5-fold increase in VLP
release while the cellular level of Pr55Gag  remained
unchanged. In contrast, over-expression of Stau1ΔNt88-
HA3 did not stimulate VLP production. To confirm these
results, dose-response assays were performed. Constant
amounts of Pr55Gag were co-expressed with increasing
amounts of either Stau155-HA3 or Stau1ΔNt88-HA3 (Figure
8B). As previously shown [51], Stau155-HA3 over-expres-
sion stimulated VLP production in a dose-dependent
manner up to 10-fold with no significant change in the
intracellular level of Pr55Gag. In contrast, Stau1ΔNt88-HA
over-expression did not lead to a significant increase of
VLP release, except at high expression levels (Figure 8C).
However, the stimulation of VLP production by
Stau1ΔNt88-HA3 was always less than that produced by
Stau155-HA3, when expressed at the same level. Analyses
of VLP production in the presence of Stau1ΔNt25-HA and
Stau1ΔNt37-HA indicated that, whereas Stau1ΔNt25-HA
enhanced VLP release, Stau1ΔNt37-HA did not (Figure 8D)
consistent with the conclusion that Stau1 molecular deter-
minant for enhanced Pr55Gag multimerization is carried
by amino acids 26 to 37.
Discussion
We previously reported that Stau1 participates in HIV-1
assembly by influencing Pr55Gag multimerization [51].Retrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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Identification of the N-terminal region of Stau155 as a regulatory sequence for HIV-1 assembly Figure 7
Identification of the N-terminal region of Stau155 as a regulatory sequence for HIV-1 assembly. (A, B) 293T cells 
were transfected as described in Figure 4B but included additional Stau155-HA deletion mutants. (A) For each condition, an 
aliquot of the cells (providing equivalent total YFP/Rluc ratio) was used for Western blot analysis using anti (α)-HA and anti 
(α)-CA antibodies. Anti (α)-GAPDH antibody was used as a loading control. (B) Another aliquot of the cells was used for 
BRET assays. Calculated BRET ratios were plotted as a function of the corresponding total YFP/Rluc ratio. (C, D) Dose 
response pr55Gag/pr55Gag BRET assays. 293T cells were transfected with fixed amounts of pCMV-pr55Gag-Rluc and pCMV-
pr55Gag-YFP and increasing amounts of different Stau1-HA expressors. (C) 48 hours later, half of the cells were lysed and ana-
lyzed by Western blotting using anti (α)-HA and anti (α)-GAPDH antibodies. *: Non-specific labelling.(D) The other half of the 
cells was used for BRET assays. BRET ratio is plotted as a function of the corresponding amount of transfected Stau1-HA 
expressor.
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Over-expression of Stau1-HA3 lacking amino acids 26 to 37 does not stimulate VLP production Figure 8
Over-expression of Stau1-HA3 lacking amino acids 26 to 37 does not stimulate VLP production. 293T cells were 
transfected with a Rev-independent Pr55Gag expressor and constant (A) or increasing (B) amounts of either Stau155-HA3 or 
Stau1ΔNt88-HA3-expressing plasmids. Twenty-four hours post-transfection, cells extracts and VLPs were prepared (see "Meth-
ods" section) and analyzed by Western blotting using anti (α)-Stau1, anti (α)-HA and anti (α)-CA antibodies. Anti (α)-calnexin 
antibodies were used as a loading control. *: Non-specific labelling. (C) Amounts of Pr55Gag in cell extracts and in VLP were 
quantitated using Quantity One (version 4.5) software (Bio-Rad) and plotted as a function of the amounts of transfected 
Stau155-HA3 and Stau1ΔNt88-HA3-expressors. (D) Cells were transfected as in (A) with two additional N-terminal Stau1 
mutants. Cell extracts and VLPs were prepared and analyzed as in (A).
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However, very little is known about the molecular mech-
anisms underlying this process. In this report, we show
that, in addition to Pr55Gag-binding via its dsRBD3
[51,52], Stau1's effect on Pr55Gag  multimerization
depends on amino acids located within its N-terminus.
Moreover, we show important contributions from both
NC zinc fingers for the Stau1/Pr55Gag interaction suggest-
ing that Stau1 influences processes that depend on these
NC sub-domains.
HIV-1 Gag mutants whose zinc fingers were disrupted,
failed to interact with Stau1 as seen in BRET and co-
immunoprecipitation assays (Figure 2). This suggests that
Stau1 directly makes contact with these structures
although we cannot rule out the possibility that these
combined mutations affect the structure of other sub-
domains of NC and potentially a Stau1-binding motif.
Interestingly, viruses that harbour these mutations do not
encapsidate Stau1 [53]. Although this phenotype could be
attributed to the loss of HIV-1 genomic RNA packaging
and to Stau1 RNA-binding activity, this strongly suggests
that Stau1 encapsidation into HIV-1 may be achieved by
the formation of a Stau1-Gag-RNA ternary complex where
Stau1 interactions with both Pr55Gag and genomic RNA
contribute to this process [51,52].
NC zinc fingers are known to play important roles during
several steps of the HIV-1 replication cycle such as
genomic RNA packaging and reverse transcription [27-
29,63]. In addition, they have been shown to be involved
in Pr55Gag assembly [5,6,29,30,46,64]. Our results with
the BRET assay that monitors direct interaction between
wild type and mutated Pr55Gag proteins are consistent
with these results. Whereas some studies reported dra-
matic defects in assembly and particle production only
when both zinc fingers were disrupted [29,46], other
showed that mutations in either of the NC zinc fingers
(especially the C-terminal one) impaired HIV-1 assembly
[30]. It is possible that the loss of one zinc finger can be
compensated by the intact one and would explain why, in
certain studies, single mutation within these motifs have
no major effects on HIV-1 assembly. Interestingly, muta-
tions in both zinc fingers are required for a complete loss
of interaction between Stau1 and Pr55Gag, mutation in
one zinc finger causing only a partial reduction. Therefore,
through its interaction with the zinc fingers, Stau1 most
likely influences steps of assembly that are controlled by
the NC zinc fingers. In addition, we do not exclude the
possibility that Stau1 also participates in other steps of
HIV-1 life cycle that depend on NC [65].
Although both Stau1 and the Gag-NC zinc fingers are
engaged in specific interactions with the genomic HIV-1
RNA, we do not have any evidence that Stau1 interacts
with NC via the genomic RNA since the Stau1-Pr55Gag
association was shown to be resistant to RNase treatment
[52]. Moreover, although the C15/49S NC mutant retains
its ability to bind RNA nonspecifically through its basic
amino acids [24-26], this mutant is unable to recruit
Stau1 supporting the idea that Stau1/Gag-NC interaction
is not bridged by RNA. Nevertheless, it is possible that
Stau1-Gag-NC interactions favour recruitment of the
genomic RNA and its subsequent trafficking and encapsi-
dation. Indeed, mutating the conserved CCHC residues of
the NC zinc fingers drastically impairs genomic RNA
packaging in newly formed virions and that of Stau1 [53].
We previously showed that Stau1 association with HIV-1
genomic RNA is required for its subsequent encapsidation
into the viral particle [53], our results now suggest that
Stau1/Gag-NC interaction is also a critical determinant for
this process. In addition, whether Stau1 interacts first with
NC or with the genomic RNA to recruit the other partner
or independently interacts with each of them through dif-
ferent pathways during HIV-1 assembly and RNA packag-
ing processes is still unknown. The identification of a
Stau1 mutant that retains its ability to associate with
genomic RNA but is defective for Pr55Gag binding will
help answer these questions.
We identified the first 88 amino acids of Stau1 as a regu-
latory motif of its activity during HIV-1 assembly. Indeed,
whereas Stau1ΔNt88-HA3 mutant is still able to interact
with Pr55Gag, it fails to enhance Pr55Gag multimerization
as seen by BRET, fractionation and VLP release assays.
These results strongly suggest that Stau1-binding to
Pr55Gag is not sufficient to influence HIV-1 assembly. They
eliminate the possibility that the observed increase in the
Pr55Gag/Pr55Gag  BRET ratio upon Stau155-HA3  over-
expression was the result of non-specific changes in the
proximity of Rluc and YFP tags due to Stau1 recruitment
towards assembly complexes. Similarly, the possibility of
major overall structural changes in Stau1ΔNt88-HA3 can be
ruled out. Indeed, the Stau1ΔNt88-HA3 mutant retains its
capacity to homo-dimerize, to enhance translation of
repressed mRNAs, to bind ribosomes and to associate
with membranes (unpublished data). Consequently, this
sequence probably confers highly specific functions to
Stau1 that are advantageous for HIV-1 assembly. It will be
interesting to study Stau1ΔNt88 encapsidation into HIV-1
as a means to determine whether the Stau1-mediated
enhancement of Pr55Gag multimerization is a prerequisite
for its intraviral packaging or whether it relies on its asso-
ciation with HIV-1 genomic RNA and on the control of
RNA selection for encapsidation [53].
How does this region control Stau1 activity? It is likely
that Stau1, in conjunction with its Pr55Gag-binding activ-
ity, attracts host factors to Pr55Gag complexes that are cru-
cial for assembly. NC-associated proteins that are also
important for the transition between specific Pr55GagRetrovirology 2008, 5:41 http://www.retrovirology.com/content/5/1/41
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assembly intermediates such as ABCE1 [44,45,47] are
good candidates. Although ABCE1/Pr55Gag  interaction
depends on NC basic amino acids [46], the disruption of
both NC zinc fingers resulted in the loss of ABCE1/
Pr55Gag association by 80% [46]. Thus, it will be impor-
tant to elucidate the functional relationship between
Stau1 and NC-associated proteins to determine if their
respective acquisition by assembly intermediates and
functions during HIV-1 assembly are simultaneous or
sequential.
Within the first 88 N-terminal amino acids of Stau1, a
region of 12 amino acids (M26RGGAYPPRYFY37) controls
Stau1 functions in regard to Pr55Gag assembly. Post-trans-
lational modifications are very common among RNA-
binding proteins such as hnRNPs and RNA helicase A and
are known to regulate their cellular proteome, function
and localization [66-69]. It is then conceivable that post-
translational modification of Stau1's N-terminal region
controls the recruitment of protein partners and/or mod-
ulates Stau1 function during HIV-1 assembly. Alterna-
tively, the N-terminal sequence may recruit ubiquitin
ligase through two potential ESCRT targeting domains
(PPRY and YPFPVPPL) [50]. In most retroviruses (except
HIV-1), the PPXY motif in Gag recruits a ubiquitin ligase
and is required for virus budding and release [50,70,71].
Resulting ubiquitination allows targeting of the PPXY-
containing protein to the ESCRT machinery located to the
multivesicular bodies. Similarly, the YPX(n)L domain that
is also present in some retroviruses (including HIV-1)
recruits the AIP1/ALIX protein that also targets the cargo
to the ESCRT [50,72,73]. Although Stau1ΔNt88-HA3 associ-
ates with membrane as efficiently as Stau155-HA3 (data
not shown), it is conceivable that these signals control the
localization of Stau1 to specific membrane compartments
to support HIV-1 assembly. Interestingly, Popov et al.
recently showed that AIP1/ALIX, through its Bro1
domain, is able to bind the NC domain of Pr55Gag in addi-
tion to p6 [64]. Strikingly, this interaction requires the
integrity of both zinc fingers and is RNA-independent, as
observed for Stau1/Pr55Gag  association. When over-
expressed, AIP1/ALIX rescues the release defect of late
domain-mutated HIV-1. Although AIP-1/ALIX over-
expression has no effect on wild type HIV-1 release [74],
in contrast to Stau1 [51], it is possible that Stau1 and AIP-
1/ALIX, through their simultaneous or sequential associa-
tion with the NC zinc fingers, cooperate during HIV-1
assembly. The putative interplay between AIP1/ALIX,
ESCRTs and Stau1 during both wild type and L-domain-
mutated virus assembly will be very interesting to explore
in future studies.
Finally, our work highlights the modular nature of the
Stau1 protein in the following ways. The double-stranded
RNA binding domain (dsRBD3) interacts with Pr55Gag
[52] whereas the N-terminus controls its activity during
HIV-1 assembly. This is supported by the fact that
Stau1Δ88-HA3 still associates with HIV-1 Gag (Figure 5)
but fails to enhance its multimerization (Figures 4, 6, 8).
Strikingly, Drosophila Stau1 orthologue, dStau, has also
been shown to function as a modular protein [75]. The
third dsRBD of dStau for example is involved in dStau
association to oskar RNA whereas the second dsRBD is
important for the microtubule-dependent transport of the
mRNP and the fifth dsRBD is involved in the derepression
of oscar mRNA translation, once localized [75].
Conclusion
In this study, we provide important new information
about the determinants in both Stau1 and Pr55Gag that
impact on HIV-1 assembly.
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